BioPlus Acquisition Corp. (BIOS)
BioPlus Acquisition Statistics
Share Statistics
BioPlus Acquisition has - shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | - |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 11.23M |
| Failed to Deliver (FTD) Shares | 100 |
| FTD / Avg. Volume | 0.28% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is 1183.3 and the forward PE ratio is null. BioPlus Acquisition's PEG ratio is -8.53.
| PE Ratio | 1183.3 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 27.4 |
| P/FCF Ratio | -8835.49 |
| PEG Ratio | -8.53 |
Enterprise Valuation
BioPlus Acquisition has an Enterprise Value (EV) of 6.11B.
| EV / Sales | 0 |
| EV / EBITDA | -5220.56 |
| EV / EBIT | -8842.52 |
| EV / FCF | -8842.52 |
Financial Position
The company has a current ratio of 1.04, with a Debt / Equity ratio of 0.02.
| Current Ratio | 1.04 |
| Quick Ratio | 1.04 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | -4.27 |
| Debt / FCF | -7.23 |
| Interest Coverage | 0.37 |
Financial Efficiency
Return on Equity is 2.32% and Return on Invested Capital is -1.33%.
| Return on Equity | 2.32% |
| Return on Assets | 2.17% |
| Return on Invested Capital | -1.33% |
| Revenue Per Employee | $- |
| Profits Per Employee | $- |
| Employee Count | undefined |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -3.17M |
| Effective Tax Rate | -158.68% |
Stock Price Statistics
The stock price has increased by -0.09% in the last 52 weeks. The beta is 0, so BioPlus Acquisition's price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | -0.09% |
| 50-Day Moving Average | 10.77 |
| 200-Day Moving Average | 10.54 |
| Relative Strength Index (RSI) | 51.09 |
| Average Volume (20 Days) | 35.93K |
Income Statement
| Revenue | n/a |
| Gross Profit | -1.17M |
| Operating Income | -1.17M |
| Net Income | 5.16M |
| EBITDA | -1.17M |
| EBIT | n/a |
| Earnings Per Share (EPS) | 0.01 |
Balance Sheet
The company has 140.3K in cash and 5M in debt, giving a net cash position of -4.86M.
| Cash & Cash Equivalents | 140.3K |
| Total Debt | 5M |
| Net Cash | -4.86M |
| Retained Earnings | -14.78M |
| Total Assets | 138.63M |
| Working Capital | -1.78M |
Cash Flow
In the last 12 months, operating cash flow was -691.47K and capital expenditures 0, giving a free cash flow of -691.47K.
| Operating Cash Flow | -691.47K |
| Capital Expenditures | 0 |
| Free Cash Flow | -691.47K |
| FCF Per Share | 0 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BIOS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 0.08% |
| FCF Yield | -0.01% |
Analyst Forecast
Currently there are no analyst rating for BIOS.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | 7.26 |
| Piotroski F-Score | 3 |